New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them

1 ) Compound of the general Formula I

wherein

A is

a) Hydroxyl,

b) branched or unbranched C 1 -C 5 alkoxy,

c) branched or unbranched Hydroxy C 1 -C 5 Alkoxy,

d) branched or unbranched O—C 1 -C 5 Alkyl-(O—C 1 -C 4 alkyl) n -O—C 1 -C 4 alkyl,

e) N(C 1 -C 5 Alkyl) 2 ,

f) NH 2 ,

g) N(H)-L,

h) O-L or

i) O—Z,

and G is

a) Hydroxyl,

b) O—Z

b) branched or unbranched O—C 1 -C 5 Alkyl,

c) branched or unbranched O—C 2 -C 5 Alkenyl,

d) branched or unbranched O—C 1 -C 5 Alkyl-(O—C 1 -C 4 alkyl) n -O—C 1 -C 4 alkyl or

e) branched or unbranched O—C 2 -C 5 Alkinyl,

and R 1 and/or R 2 , independently separate are

a) Hydrogen,

b) branched or unbranched 19 F—C 1 -C 10 Alkoxy,

c) branched or unbranched 19 F—C 1 -C 10 Alkyl,

d) branched or unbranched 19 F—C 2 -C 10 Alkenyl,

e) branched or unbranched 19 F—C 2 -C 10 Alkinyl,

f) substituted or unsubstituted 19 F—C 6 -C 10 mono- or bicyclic Aryl,

g) substituted or unsubstituted 19 F-alkyl-C 6 -C 10 mono- or bicyclic Aryl

h) substituted or unsubstituted 19 F—C 5 -C 10 mono- or bicyclic Heteroaryl,

i) substituted or unsubstituted 19 F-alkyl-C 5 -C 10 mono- or bicyclic Heteroaryl

j) substituted or unsubstituted 19 F—C 3 -C 6 Cyclo-Alkyl,

k) substituted or unsubstituted 19 F-alkyl-C 3 -C 6 Cyclo-Alkyl

l) Hydroxyl,

m) branched or unbranched C 1 -C 5 Alkyl or

n) branched or unbranched C 1 -C 5 Alkoxy

wherein alkyl is optionally interrupted or is replaced by O, S or N,

with the proviso that one of the substituent R 1 or R 2 comprises 19 F atom and the other substituent comprises no 19 F atom,

and L is

a) branched or unbranched C 1 -C 5 Alkyl,

b) branched or unbranched C 2 -C 5 Alkenyl,

c) branched or unbranched C 1 -C 5 Alkyl-(O—C 1 -C 4 alkyl) n -O—C 1 -C 4 alkyl or

d) branched or unbranched C 2 -C 5 Alkinyl,

and Z is a metal ion equivalent,

with the meaning of n=0, 1, 2 or 3,

and

wherein mixtures of all possible diastereomers and/or enantiomers as well as enantiomerically pure compounds and pharmaceutical salts thereof are comprised.

2 ) Compound according to claim 1 wherein R 1 is 19 F and R 2 is hydrogen.

3 ) Compound according to claims 1

4 ) Pharmaceutical composition comprising one compound or more compounds of general Formula I and a pharmaceutical acceptable carrier.

5 ) Method for obtaining compound(s) of general Formula I according to claim 1 by reacting a non-fluorinated compound of formula I with a fluorine atom or derivative.

6 ) Compound(s) of general Formula I according to claim 1 for use as a medicament.

7 ) A method comprising using Compound(s) of general Formula I according to claim 1 for the preparation of a medicament for use as an inhibitor of proliferative diseases in a patient.

8 ) A method according to claim 7 wherein the medicament is for treating, preventing or alleviating proliferative diseases.

9 ) A method for treating proliferative diseases comprising administering to an individual in need thereof a therapeutically effective amount of Compound(s) of general Formula I as defined in claim 1 .

10 ) A method according to claim 7 , wherein the compound of formula I is to be administered orally, parenterally, rectally, or locally.

11 ) Compound(s) of general Formula I according to claim 1 for use as imaging agent.

12 ) A method comprising using Compound(s) of general Formula I according to claim 1 for the manufacturing of an imaging agent for imaging proliferative diseases in a patient.

13 ) A method according to claim 13 wherein the imaging agent is a Magnetic Resonance Imaging (MRI) agent.

14 ) A method for imaging proliferative diseases comprising administering to an individual in need thereof a therapeutically effective amount of Compound(s) of general Formula I as defined in claim 1 .

15 ) A method according to claim 7 , wherein the compound of formula I is to be administered orally, parenterally, rectally, or locally.

16 ) Kit comprising Compound(s) of general Formula I as defined in claim 1 .